Here are 21 key notes on orthopedic and spine device companies over the past week.
Amendia entered into a strategic venture with Promimic.
Bioventus launched SUPARTZ FX, a non-surgical, non-pharmacologic therapy for knee osteoarthritis.
The Hospital for Special Surgery in New York presented data from the first U.S. study of BONESUPPORT's CERAMENT with Gentamicin in an infected rat model at the European Bone & Joint Infection Society.
Johnson & Johnson's orthopedics subsidiary DePuy Synthes reported a drop in international and overall sales in the third quarter of 2015.
Ellipse Technologies filed for an initial public offering of up to $75 million.
IlluminOss Medical recently entered into an agreement with Orthovative to distribute the IlluminOss System in Germany.
Integra LifeSciences Holdings' company shares increased 0.97 percent during the week of Oct. 12 to Oct. 16.
The FDA approved an expansion for the InVivo pilot study for the investigational Neuro-Spinal Scaffold.
Global medical device company K2M Group Holdings' shares decreased 4.2 percent on Oct. 20.
LDR's ROI-C Cervical Cage received FDA clearance for use with allograft.
Life Spine announced the limited release of the CENTERLINE Thoracolumbar Spinal System.
Medtronic became a founding donor to the Smithsonian's National Museum of African American History and Culture when the company's philanthropic arm donated $2 million.
Misonix demonstrated its new BoneScalpel MIS Platform at the North American Spine Society meeting in October, training more than 120 spine surgeons.
SeaSpine appointed Patrick Keran to general counsel.
SeaSpine also launched the Cambria NanoMetalene interbody device.
Equity analysts are predicting that Smith & Nephew is ripe for an acquisition bid.
Soft Tissue Regeneration initiated a randomized and controlled clinic study for its L-C-ligament device in Europe.
Stryker's consolidated net sales were $2.4 billion in the third quarter of 2015, a 1.3 percent increase.
Ziehm Imaging and the Navigation Division of Stryker have signed a co-marketing agreement.
Also, Stryker's Interventional Spine business received FDA clearance for its VertaPlex HV, which treats sacral insufficiency fractures.
Xtant Medical's common stock has been approved for listing on the NYSE MKT stock exchange.